general talk, page-273

if you are thinking of them as only a drug developer you wouldn't be thinking of revenue or money flowing for at least a decade - the typical time to get a drug approved for that revenue tap to turn on.

the company has always focused on its clinical services to capture RWD and feed into its drug dev arm.

this is what makes the company unique globally. that the RWD of the Australian special access schemes can be prescribed today to feed into the dev work.

pax turns over about 5 million alone on top of the other clinics. will be good for it to pop up in next financial / q reports

I don't see companies at all having pivot it's still core to the special access schemes the only pivot from cannabis to mdma when Aus became first in the world. (a far more unique opportunity) one you have to go after